Multiple myeloma: Chemotherapy or transplantation in the era of new drugs

Antonio Palumbo, S Vincent Rajkumar

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Objective: To review the current results of studies incorporating novel agents in multiple myeloma (MM) and discuss the role of autologous stem-cell transplantation (ASCT) in the era of new active drugs for the treatment of this disease. The outlook for patients with symptomatic MM is changing with the introduction of bortezomib, thalidomide, and lenalidomide into the repertoire of available chemotherapeutic agents. Compared with standard chemotherapy, a survival benefit has been reported for the first time in 30 yrs. Methods: Articles published in English between 1969 and 2008 were identified by searching PubMed for 'myeloma', 'diagnosis', 'thalidomide', 'bortezomib', 'lenalidomide', 'dexamethasone', 'prednisone', 'doxorubicin', 'cyclophosphamide', 'melphalan', 'combination chemotherapy', and 'autologous transplantation'. Results: In randomized studies, bortezomib, thalidomide, and lenalidomide have each been combined with dexamethasone, alkylating agents, or doxorubicin, and such combinations resulted in significant improvement in progression-free survival. Conclusions: The incorporation of new drugs as induction therapy along with ASCT appears to produce very good partial response rates, slightly superior to those achieved by conventional chemotherapy with new drugs. How to best optimize induction, consolidation, and maintenance therapy and how to best select and prepare patients for ASCT are still to be determined. Randomized trials are needed to directly compare the current best chemotherapeutic approach with best ASCT strategies and to guide clinical practice for patients with MM.

Original languageEnglish (US)
Pages (from-to)379-390
Number of pages12
JournalEuropean Journal of Haematology
Volume84
Issue number5
DOIs
StatePublished - May 2010

Fingerprint

Stem Cell Transplantation
Multiple Myeloma
Thalidomide
Transplantation
Drug Therapy
Pharmaceutical Preparations
Doxorubicin
Dexamethasone
Melphalan
Autologous Transplantation
Alkylating Agents
Prednisone
Combination Drug Therapy
PubMed
Cyclophosphamide
Disease-Free Survival
Therapeutics
Survival
lenalidomide
Bortezomib

Keywords

  • Autologous stem-cell transplantation
  • Chemotherapeutic agents
  • Induction therapy
  • Lenalidomide
  • Multiple myeloma
  • Response rates

ASJC Scopus subject areas

  • Hematology

Cite this

Multiple myeloma : Chemotherapy or transplantation in the era of new drugs. / Palumbo, Antonio; Rajkumar, S Vincent.

In: European Journal of Haematology, Vol. 84, No. 5, 05.2010, p. 379-390.

Research output: Contribution to journalArticle

@article{a6437e3cd7644265b1e732ccf602f318,
title = "Multiple myeloma: Chemotherapy or transplantation in the era of new drugs",
abstract = "Objective: To review the current results of studies incorporating novel agents in multiple myeloma (MM) and discuss the role of autologous stem-cell transplantation (ASCT) in the era of new active drugs for the treatment of this disease. The outlook for patients with symptomatic MM is changing with the introduction of bortezomib, thalidomide, and lenalidomide into the repertoire of available chemotherapeutic agents. Compared with standard chemotherapy, a survival benefit has been reported for the first time in 30 yrs. Methods: Articles published in English between 1969 and 2008 were identified by searching PubMed for 'myeloma', 'diagnosis', 'thalidomide', 'bortezomib', 'lenalidomide', 'dexamethasone', 'prednisone', 'doxorubicin', 'cyclophosphamide', 'melphalan', 'combination chemotherapy', and 'autologous transplantation'. Results: In randomized studies, bortezomib, thalidomide, and lenalidomide have each been combined with dexamethasone, alkylating agents, or doxorubicin, and such combinations resulted in significant improvement in progression-free survival. Conclusions: The incorporation of new drugs as induction therapy along with ASCT appears to produce very good partial response rates, slightly superior to those achieved by conventional chemotherapy with new drugs. How to best optimize induction, consolidation, and maintenance therapy and how to best select and prepare patients for ASCT are still to be determined. Randomized trials are needed to directly compare the current best chemotherapeutic approach with best ASCT strategies and to guide clinical practice for patients with MM.",
keywords = "Autologous stem-cell transplantation, Chemotherapeutic agents, Induction therapy, Lenalidomide, Multiple myeloma, Response rates",
author = "Antonio Palumbo and Rajkumar, {S Vincent}",
year = "2010",
month = "5",
doi = "10.1111/j.1600-0609.2010.01431.x",
language = "English (US)",
volume = "84",
pages = "379--390",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Multiple myeloma

T2 - Chemotherapy or transplantation in the era of new drugs

AU - Palumbo, Antonio

AU - Rajkumar, S Vincent

PY - 2010/5

Y1 - 2010/5

N2 - Objective: To review the current results of studies incorporating novel agents in multiple myeloma (MM) and discuss the role of autologous stem-cell transplantation (ASCT) in the era of new active drugs for the treatment of this disease. The outlook for patients with symptomatic MM is changing with the introduction of bortezomib, thalidomide, and lenalidomide into the repertoire of available chemotherapeutic agents. Compared with standard chemotherapy, a survival benefit has been reported for the first time in 30 yrs. Methods: Articles published in English between 1969 and 2008 were identified by searching PubMed for 'myeloma', 'diagnosis', 'thalidomide', 'bortezomib', 'lenalidomide', 'dexamethasone', 'prednisone', 'doxorubicin', 'cyclophosphamide', 'melphalan', 'combination chemotherapy', and 'autologous transplantation'. Results: In randomized studies, bortezomib, thalidomide, and lenalidomide have each been combined with dexamethasone, alkylating agents, or doxorubicin, and such combinations resulted in significant improvement in progression-free survival. Conclusions: The incorporation of new drugs as induction therapy along with ASCT appears to produce very good partial response rates, slightly superior to those achieved by conventional chemotherapy with new drugs. How to best optimize induction, consolidation, and maintenance therapy and how to best select and prepare patients for ASCT are still to be determined. Randomized trials are needed to directly compare the current best chemotherapeutic approach with best ASCT strategies and to guide clinical practice for patients with MM.

AB - Objective: To review the current results of studies incorporating novel agents in multiple myeloma (MM) and discuss the role of autologous stem-cell transplantation (ASCT) in the era of new active drugs for the treatment of this disease. The outlook for patients with symptomatic MM is changing with the introduction of bortezomib, thalidomide, and lenalidomide into the repertoire of available chemotherapeutic agents. Compared with standard chemotherapy, a survival benefit has been reported for the first time in 30 yrs. Methods: Articles published in English between 1969 and 2008 were identified by searching PubMed for 'myeloma', 'diagnosis', 'thalidomide', 'bortezomib', 'lenalidomide', 'dexamethasone', 'prednisone', 'doxorubicin', 'cyclophosphamide', 'melphalan', 'combination chemotherapy', and 'autologous transplantation'. Results: In randomized studies, bortezomib, thalidomide, and lenalidomide have each been combined with dexamethasone, alkylating agents, or doxorubicin, and such combinations resulted in significant improvement in progression-free survival. Conclusions: The incorporation of new drugs as induction therapy along with ASCT appears to produce very good partial response rates, slightly superior to those achieved by conventional chemotherapy with new drugs. How to best optimize induction, consolidation, and maintenance therapy and how to best select and prepare patients for ASCT are still to be determined. Randomized trials are needed to directly compare the current best chemotherapeutic approach with best ASCT strategies and to guide clinical practice for patients with MM.

KW - Autologous stem-cell transplantation

KW - Chemotherapeutic agents

KW - Induction therapy

KW - Lenalidomide

KW - Multiple myeloma

KW - Response rates

UR - http://www.scopus.com/inward/record.url?scp=77951034358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951034358&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0609.2010.01431.x

DO - 10.1111/j.1600-0609.2010.01431.x

M3 - Article

C2 - 20345446

AN - SCOPUS:77951034358

VL - 84

SP - 379

EP - 390

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 5

ER -